Uso de resúmenes de evidencia para informar el tratamiento farmacológico de personas con sospecha o diagnóstico de infección respiratoria por SARS CoV-2 / COVID-19

Palabras clave: COVID-19; síndrome respiratorio agudo grave; tratamiento farmacológico; antivirales; SARS-CoV-2

Resumen

Los resúmenes de evidencia facilitan la transferencia de conocimiento para los tomadores de decisiones en salud. Cuando se fundamentan en revisiones sistemáticas de literatura su oportunidad puede verse afectada por requerirse mayor tiempo en su elaboración, por lo que se prefiere el uso de nuevas metodologías. El presente trabajo aplica la metodología de revisiones sistemáticas rápidas para un escenario de decisión inmediata en el contexto del tratamiento farmacológico de personas infectadas por SARS CoV-2 facilitando resúmenes de evidencia para 14 preguntas de interés clínico. Los medicamentos incluyen algunos propuestos para tratamiento tales como la hidroxicloroquina, azitromicina, oseltamivir, remdesivir, umifenovir, nelfinavir, lopinavir/ritonavir ribavirina y teicoplanina, también se incluyen los medicamentos de soporte e incluidos en el manejo como los corticosteroides en diferentes escenarios clínicos, así como medicamentos que generan duda en su uso concomitante en la enfermedad COVID-19 como son los AINES, los IECA y los ARA II.

Descargas

La descarga de datos todavía no está disponible.

Referencias

1. Munn Z, Lockwood C, Moola S. The Development and Use of Evidence Summaries for Point of Care Information Systems: A Streamlined Rapid Review Approach. Worldviews Evidence-Based Nurs. 2015;12(3):131-38. https://doi.org/10.1111/wvn.12094.
2. Andermann A, Pang T, Newton JN, Davis A, Panisset U. Evidence for Health II: Overcoming barriers to using evidence in policy and practice. Heal Res Policy Syst. 2016;14(17):https://doi.org/10.1186/s12961-016-0086-3.
3. Patnode CD, Eder ML, Walsh ES, Viswanathan M, Lin JS. The Use of Rapid Review Methods for the U.S. Preventive Services Task Force. Am J Prev Med. 2018;54(1S1):S19-25. https://doi.org/10.1016/j.amepre.2017.07.0.
4. Tricco AC, Langlois E V, Straus SE. World Health Organization, Alliance for Health Policy and Systems Research. Rapid Reviews To Strengthen Health Policy and Systems: a Practical Guide [Internet]. 2017. Available from: https://www.who.int/alliance-hpsr/resources/publications/rapid-review-guide/en/
5. Gutierrez I. Protocolos de búsqueda bibliográfica. Vitoria-Gasteiz [Internet]. España; 2002. Available from: https://www.osakidetza.euskadi.eus/contenidos/informacion/osteba_formacion_/es_def/adjuntos/bibliografia.pdf
6. Dobbins M. Rapid Review Guidebook. Steps for conducting a rapid review [Internet]. Canada: National Collaborating Centre for Methods and Tools; 2017. 25 p. Available from: https://www.nccmt.ca/uploads/media/media/0001/01/a816af720e4d587e13da6bb307df8c907a5dff9a.pdf
7. Lehoux P, Tailliez S, Denis JL, Hivon M. Redefining health technology assessment in Canada: Diversification of products and contextualization of findings. Int J Technol Assess Health Care. 2004;20(3):325-36. https://doi.org/10.1017/s026646230400114x.
8. Keralty. Instituto Global de Excelencia Clínica. Manual de revisiones sistemáticas rápidas. Colombia; 2019.
9. Agencia Española de Medicamentos y Productos Sanitarios. La AEMPS informa que ningún dato indica que el ibuprofeno agrave las infecciones por COVID-19 [Internet]. 2020. p. 1. Available from: https://www.aemps.gob.es/informa/notasinformativas/medicamentosusohumano-3/2020-medicamentosusohumano-3/la-aemps-informa-que-ningun-dato-indica-que-el-ibuprofeno-agrave-las-infecciones-por-covid-19/
10. Little P, Moore M, Kelly J, Williamson I, Leydon G, McDermott L, et al. Ibuprofen, paracetamol, and steam for patients with respiratory tract infections in primary care: pragmatic randomised factorial trial. BMJ. 2013;347(f6041):https://doi.org/10.1136/bmj.f6041.
11. Basille D, Plouvier N, Trouve C, Duhaut P, Andrejak C, Jounieaux V. Non-steroidal Anti-inflammatory Drugs may Worsen the Course of Community-Acquired Pneumonia: A Cohort Study. Lung. 2017;195(2):201-8. https://doi.org/10.1007/s00408-016-9973–1.
12. AEMPS. Ibuprofeno. Ficha Técnica. [Internet]. 2020. Available from: https://cima.aemps.es/cima/pdfs/es/ft/71436/FichaTecnica_71436.html.pdf
13. Adedeji AO, Severson W, Jonsson C, Singh K, Weiss SR, Sarafianos SG. Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus Entry That Act by Three Distinct Mechanisms. J Virol. 2013;87(14):8017-28. https://doi.org/10.1128/JVI.00998-13.
14. Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020;https://doi.org/10.1016/j.bbrc.2020.02.071.
15. Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;https://doi.org/10.1093/jtm/taaa041.
16. American College of Cardiology. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 [Internet]. 2020. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19
17. European Society of Cardiology. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers [Internet]. 2020. Available from: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang
18. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;https://doi.org/10.1016/S2213-2600(20)30116-8.
19. Schneider M, Ackermann K, Stuart M, Wex C, Protzer U, Schätzl HM, et al. Severe Acute Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132 due to Proteasome-Independent Inhibition of M-Calpain. J Virol. 2012;86(18):10112-22 https://doi.org/10.1128/JVI.01001-12.
20. Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11(1):59. https://doi.org/10.3390/v11010059.
21. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.
22. Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013;23(2):300-2. https://doi.org/10.1038/cr.2012.165.
23. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2(69):https://doi.org/10.1186/1743-422X-2-69.
24. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)301.
25. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected [Internet]. Who. 2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/178529/WHO_MERS_Clinical_15.1_eng.pdf;jsessionid=FD47E0105E3B3EBD09C680C4706428BC?sequence=1
26. Sociedad italiana de enfermedades infecciosas y tropicales SIMIT. Guía de manejo terapéutico y de soporte para pacientes con infección por coronavirus COVID-19. 2020.
27. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA. 2020;https://doi.org/10.1001/jama.2020.2648.
28. Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res. 2020;177(104762):https://doi.org/10.1016/j.antiviral.2020.104762.
29. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-3. https://doi.org/10.5582/bst.2020.01047.
30. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;https://doi.org/10.1093/cid/ciaa237.
31. Coronavirus : diagnostiquons et traitons! Premiers résultats pour la chloroquine [Internet] [Internet]. 2020. Available from: https://youtu.be/n4J8kydOvbc
32. Menzel M, Akbarshahi H, Bjermer L, Uller L. Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. Sci Rep. 2016;6(28698):https://doi.org/10.1038/srep28698.
33. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;https://doi.org/10.1016/j.ijantimicag.2020.105949.
34. World Health Organization- Malaria Policy Advisory Committee Meeting. The Cardiotoxicity of Antimalarials [Internet]. 2017. Available from: https://www.who.int/malaria/mpac/mpac-mar2017-erg-cardiotoxicity-report-session2.pdf
35. American College of Cardiology. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 [Internet]. 2020. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19
36. Asencio E, Acunzo R, Saad E, Sáenz LC. Recomendaciones para la medición del intervalo QT durante el uso de medicamentos para el tratamiento de infección por COVID-19. 2020.
37. Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2019;2(2):CD010406. https://doi.org/doi:10.1002/14651858.CD0.
38. BMJ. Best practice. COVID-19 [Internet]. Last updated: Mar 12, 2020. Available from: https://bestpractice.bmj.com/topics/en-gb/3000168/pdf/3000168/COVID-19.pdf
39. Zhou Y-H, Qin Y-Y, Lu Y-Q, Sun F, Yang S, Harypursat V, et al. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia. Chin Med J (Engl). 2020;https://doi.org/10.1097/CM9.0000000000000791.
40. Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020;5(18):https://doi.org/10.1038/s41392-020-0127-9.
41. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225):683-4. https://doi.org/10.1016/S0140-6736(20)30361.
42. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-75. https://doi.org/10.1016/S0140-6736(20)3031.
43. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virol Sin. 2020;https://doi.org/10.1007/s12250-020-00207-4.
44. Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. [Management of corona virus disease-19 (COVID-19): the Zhejiang experience]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(1).
45. Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med. 2020;46(2):315-28. https://doi.org/10.1007/s00134-020-05943–5.
46. Ling Y, Xu S-B, Lin Y-X, Tian D, Zhu Z-Q, Dai F-H, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020;https://doi.org/10.1097/CM9.0000000000000774.
47. Meduri GU, Bridges L, Shih MC, Marik PE, Siemieniuk RAC, Kocak M. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients’ data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med. 2016;42(5):829-40. https://doi.org/10.1007/s00134-015-4095–4.
48. Meduri GU, Siemieniuk RAC, Ness RA, Seyler SJ. Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS. J Intensive Care. 2018;6(53):https://doi.org/10.1186/s40560-018-0321-9.
49. Yao T, Qian J, Zhu W, Wang Y, Wang G. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option. J Med Virol. 2020;https://doi.org/10.1002/jmv.25729.
50. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;https://doi.org/10.1056/NEJMoa2001282.
51. Han W, Quan B, Guo Y, Zhang J, Lu Y, Feng G, et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J Med Virol. 2020;92(5):461-3. https://doi.org/10.1002/jmv.25711.
52. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14(1):64-8. https://doi.org/10.5582/bst.2020.01030.
53. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: The application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35(7):e88. https://doi.org/10.3346/jkms.2020.35.e88.
54. China National Health Commission (2020). Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition) [Internet]. Available from: http://kjfy.meetingchina.org/msite/news/show/cn/3337.html
55. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020;92(5):479-90. https://doi.org/10.1002/jmv.25707.
56. Jarvis B, Faulds D. Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs. 1998;56(1):147-67. https://doi.org/10.2165/00003495-199856010.
57. Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun. 2004;318(3):719-25. https://doi.org/10.1016/j.bbrc.2004.04.083.
58. Agencia Española de medicamentos y productos sanitarios. Oseltamivir. Ficha técnica. [Internet]. Available from: https://cima.aemps.es/cima/pdfs/ft/02222003/FT_02222003.pdf
59. Li H, Wang YM, Xu JY, Cao B. [Potential antiviral therapeutics for 2019 Novel Coronavirus]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(0):E002. https://doi.org/10.3760/cma.j.issn.1001-0939.
60. ClinicalTrials.gov. A Prospective, Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia. ClinicalTrials.gov. NCT0425501.
61. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221-18. https://doi.org/10.1128/mBio.00221-18.
62. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60. https://doi.org/10.5582/ddt.2020.01012.
63. Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020;https://doi.org/10.1128/AAC.00399-20.
64. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69-71. https://doi.org/10.5582/bst.2020.01020.
65. Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, et al. Advances in respiratory virus therapeutics – A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019;167(45–67):https://doi.org/10.1016/j.antiviral.2019.04.006.
66. Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248(117477):https://doi.org/10.1016/j.lfs.2020.117477.
67. Du B, Qiu HB, Zhan X, Wang YS, Kang HYJ, Li XY, et al. [Pharmacotherapeutics for the new coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(3):173-6. https://doi.org/10.3760/cma.j.issn.1001-093.
68. Elfiky A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020;https://doi.org/10.1016/j.lfs.2020.117592.
69. ClinicalTrials.gov. Ribavirin [Internet]. Available from: https://clinicaltrials.gov/ct2/results?cond=Coronavirus&term=Ribavirin&cntry=&state=&city=&dist=
70. Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, et al. Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem. 2016;291(17):9218-9232. https://doi.org/10.1074/jbc.M116.716100.
71. Baron SA, Devaux C, Colson P, Raoult D, Rolain J-M. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? Int J Antimicrob Agents. 2020;https://doi.org/10.1016/j.ijantimicag.2020.105944.
72. Balzarini J, Keyaerts E, Vijgen L, Egberink H, De Clercq E, Van Ranst M, et al. Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. Antiviral Res. 2006;72(1):20-33. https://doi.org/10.1016/j.antiviral.2006.03.
73. Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, et al. Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv. 2020;
74. Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019:a retrospective cohort study. J Infect. 2020;https://doi.org/10.1016/j.jinf.2020.03.002
Publicado
2020-04-14
Cómo citar
1.
Yomayusa González N, Low Padilla E, De La Hoz Siegler I, Chacón K, Acevedo Peña J, Barrero Garzón L, Barrera A, Tolosa N, Castillo A, Guevara Pulido F, Castelblanco D, Pinzón Florez C, Mendivelso Duarte F, Cantor Cruz F, Castillo Gutiérrez A, Gómez Gómez O, Ávila A, Guevara C, Álvarez Moreno C, Rojas Gambasica J, Arbeláez Duque CM, García Guarín B, Cárdenas Rodríguez M, Robayo Rodríguez S, Torres Castro M. Uso de resúmenes de evidencia para informar el tratamiento farmacológico de personas con sospecha o diagnóstico de infección respiratoria por SARS CoV-2 / COVID-19. Rev. Colomb. Nefrol. [Internet]. 14 de abril de 2020 [citado 4 de junio de 2020];7(Supl 2). Disponible en: https://revistanefrologia.org/index.php/rcn/article/view/407
Sección
Artículo de revisión